SRZN
Surrozen, Inc.
OpenVolumeMkt capP/EEPSDiv yield
Day – 52-wk –
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Surrozen has 4 disclosed suppliers and 2 disclosed customers in SEC filings.
Last reportshaded = implied▲▼ = realized× = |realized| ÷ implied
Expected move
No implied move.
SentenceFor example, in October 2022, we executed a strategic partnership with Boehringer Ingelheim for the research and development of SZN-413 for the treatment of retinal diseases.
SRZN 10-Kaccession 0001193125-26-119818
SentenceOur public warrants are issued in registered form under an amended and restated warrant agreement by and between Continental Stock Transfer & Trust Company, as the warrant agent, and us, dated as of March 31, 2023, or the Warrant Agreement.
SRZN 10-Kaccession 0001193125-26-119818
SentenceWe are party to an exclusive license agreement with Stanford University covering patents relevant to one or more product candidates, and may need to obtain additional licenses from others to advance our research and development activities or allow the commercialization of our current and future product candidates we may identify and pursue.
SRZN 10-Kaccession 0001193125-26-119818
SentenceIn August 2025, we entered into a sales agreement with TD Securities (USA) LLC, or TD Cowen, to issue and sell up to $50.0 million of shares of common stock, or the 2025 ATM.
SRZN 10-Kaccession 0001193125-26-119818
SentenceUnder the terms of the CLA, Boehringer Ingelheim paid us a non-refundable upfront payment of $12.5 million less applicable withholding tax and agreed to pay success-based milestone payments up to $587.0 million and mid-single digit to low-double digit royalties on net sales of the licensed products should any reach commercialization.
SRZN 10-Kaccession 0001193125-26-119818
SentenceIn exchange for our research services, TCGFB agreed to pay us up to $6.0 million in the aggregate, plus any third-party costs, and issued us a warrant exercisable for up to 3.4 million shares of TCGFB common stock at an exercise price of $0.0001 per share based on certain vesting conditions.
SRZN 10-Kaccession 0001193125-26-119818
Surrozen, Inc.
28.82
Largest filed tie
—